Viewing data from:

VEREGEN

NDA

SINECATECHINS | N021902 | ANI PHARMACEUTICALS INC

1 strength1 unique patent0 unique exclusivities

Patent Timeline

1 unique patent by expiration date

Expiring < 1yr (1)Today

Today

Oct. 2, 2026

PTAB Proceedings

No IPR/PGR/CBM challenges found at the Patent Trial and Appeal Board

Patent Reexaminations

No ex parte or inter partes reexamination proceedings found at USPTO

Hatch-Waxman Litigation

No ANDA patent litigation cases (NOS 835) matched from PACER

Citizen Petitions

No FDA citizen petitions matched from Regulations.gov

Clinical Trials

No clinical trials found on ClinicalTrials.gov for this drug

Medicare Part D Spending

CMS annual spending data for Veregen (2023)

Total Spending

$262K

Total Claims

138

Beneficiaries

Avg Cost/Unit

$55.62

Spending Trend

$335K(2019)→$223K(2020)→$273K(2021)→$239K(2022)→$262K(2023)

YoY Change:+10.8%

5yr CAGR:+5.1%

Source: CMS Medicare Part D Spending by Drug (2023). Shows gross drug cost under Part D.

Approval Letters

7 letters from Drugs@FDA

Source: Drugs@FDA application documents.

Products (1)

#001 — 15%

RLD

1 patent0 exclusivities▴

OINTMENT;TOPICAL | Approved: Oct 31, 2006

Patent #	Expiration	PED	Drug Substance	Drug Product	Use Code	Delist
7858662	Oct 2, 2026	—	—	Yes		—